Celltrion Presents Remsima SC Post-Hoc Analysis at ECCO 2026
Celltrion released new post-hoc analysis from its phase 3 trial of Remsima SC in IBD patients at the ECCO 2026 congress. The data showed rapid clinical response after treatment gaps and maintained efficacy over 102 weeks. The company also highlighted its unique offering of infliximab in three formulations.
Celltrion released new post-hoc analysis results from a phase 3 clinical trial of its subcutaneous infliximab formulation, Remsima SC (known as Zymfentra in the U.S.), during the 21st European Crohn’s and Colitis Organization (ECCO) Congress in Stockholm, Sweden. The analysis, presented on the first day of the congress, involved patients with Crohn’s disease or ulcerative colitis.
The data revealed that most patients who received a 240mg dose of Remsima SC after a treatment gap of at least 16 weeks following intravenous therapy experienced a rapid recovery in clinical response. Efficacy and safety were maintained stably throughout a 102‑week follow‑up period. The analysis suggested that Remsima SC serves as a meaningful treatment strategy for resuming therapy, particularly since drug skips occur frequently in patients with IBD for various clinical or non‑clinical reasons.
During a symposium titled “treatment optimization through the infliximab SC formulation,” experts discussed strategies for improving patient care based on real‑world clinical data. Separate sessions at the company’s booth addressed the clinical implications of long‑term results after switching from intravenous to subcutaneous administration and the necessity of combination therapy with TNF inhibitors.
Celltrion emphasized its competitive edge as the only firm to offer infliximab in three formats: lyophilized intravenous, high‑concentration liquid intravenous, and subcutaneous formulations. The recently approved high‑concentration liquid intravenous product is expected to contribute to the growth of Remsima prescriptions by improving convenience and efficiency in medical settings through minimized preparation time and required personnel.
The company plans to expand its presence in the market by offering four different treatments for IBD, including Remsima, Remsima SC, Yuflyma, and Steqeyma. By providing various options, it aims to increase prescription preference among healthcare providers and drive substantial sales growth.
“The company continues to release evidence‑based data for its treatments at the congress every year and is observing growing interest from medical professionals,” a company official stated. “The company will continue research based on medical needs and develop innovative formulations to strengthen its competitiveness and market position in the autoimmune disease sector.”